ARQT Arcutis Biotherapeutics, Inc.

NASDAQ
$27.00

Arcutis Biotherapeutics, Inc. (ARQT) is expected to report earnings on February 3, 2027, after the market close. The consensus earnings estimate is $0.20 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -6.9% since its last earnings release on November 4, 2026.

Arcutis Biotherapeutics Missed Consensus Estimates, Raises Guidance In-line with Estimates
Wednesday, November 4, 2026 · 4:00 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 3
Wednesday · 4:00 PM ET
Earnings Whisper
-
vs $0.20
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $27.00

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc. is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions.

Sector

Healthcare

Industry

Drug Manufacturers/Other

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.